CD274 and neoplasm: Designed with high affinity for specific membrane-bound receptors, such as PD-1, PDL-1, and CTLA-4 [1], such antibodies block mechanisms that enable cancer cells to evade the anti-tumor activity of T-cells, which, in principle, enables the immune system to recognize and kill the malignant cells.